The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
Return of Venezuelan crude could cut US fuel oil imports
By Anushree Mukherjee and Enes Tunagur BENGALURU/LONDON Jan 27 (Reuters) – U.S. demand for imported fuel oil is set to…
Bitcoin bears dominate: odds of year-end price below $90,000 rise
By Gertrude Chavez-Dreyfuss NEW YORK (Reuters) -The likelihood of bitcoin ending the year below $90,000 has risen to 50%, according…
U.S. stocks open higher as investors await Fed rate cut decision
Dec 8 (Reuters) – Wall Street’s main indexes opened modestly higher on Monday as investors priced in expectations that the…